Bernini F, Catapano A L, Corsini A, Fumagalli R, Paolétti R
Institute of Pharmacological Sciences, University of Milan, Italy.
Am J Cardiol. 1989 Nov 7;64(17):129I-133I; discussion 133I-134I. doi: 10.1016/0002-9149(89)90970-3.
The arterial accumulation of cholesterol and calcium is a hallmark of atherosclerosis. Calcium antagonists (CAs) lessen the severity of experimentally induced atherosclerosis in cholesterol-fed animals. The reduction of aortic cholesterol is one of the most striking findings. This effect is achieved without a reduction of plasma lipid or blood pressure, and is probably related to an interference of CAs with lipid metabolism in the arterial wall. To what extent these properties of CAs are due to their ability to block calcium channels still remains to be addressed. This report briefly discusses the available in vivo and in vitro evidence for the antiatherosclerotic properties of CAs, and outlines the possible mechanisms by which these compounds affect cellular lipid metabolism.
胆固醇和钙在动脉中的蓄积是动脉粥样硬化的一个标志。钙拮抗剂(CAs)可减轻在喂食胆固醇的动物中实验性诱导的动脉粥样硬化的严重程度。主动脉胆固醇的降低是最显著的发现之一。这种作用在不降低血浆脂质或血压的情况下即可实现,并且可能与CAs对动脉壁脂质代谢的干扰有关。CAs的这些特性在多大程度上归因于它们阻断钙通道的能力仍有待探讨。本报告简要讨论了关于CAs抗动脉粥样硬化特性的现有体内和体外证据,并概述了这些化合物影响细胞脂质代谢的可能机制。